Potencial of Aloin B Compound and its Derivatives as Type-2 Antidiabetic

Abstract

Type-2 diabetes mellitus occurs due to suboptimal insulin function (insulin resistance) or decreased insulin function. Type-2 diabetes mellitus treatment is chronic and lifelong. One of the treatments is the use of insulin and oral anti-diabetic drugs. This treatment requires a long period of time and can cause unwanted side effects. Therefore, alternative treatments are needed with minimal side effects by utilizing herbal plants containing Aloin B compounds because they have been proven to be used as antidiabetic agents. These compounds can be found from the Aloe Vera plant (Aloe Vera l.). The aim of this study was to find compounds derived from Aloin B compounds that have the most potential as anti-diabetic type-2 by inhibiting the pancreatic α-amylase enzyme (code: 1B2Y) in breaking down starch in the body. The certainty of the presence of the compound Aloin B in the flesh of the aloe plant was confirmed by the LC-MS test. This research was conducted using the Quantitative Structure-Activity Relationship (QSAR) and Molecular Bonding method. The results showed that the ID S22 compound with the IUPAC name (S)-10-amino-1,2,8-trihydroxy-6- (hydroxymethyl) -10- ((2R,3R,4S,5S,6R) -2,3, 4,5-tetrahydroxy–6(hydroxymethyl) tetrahydro-2H-piran-2-yl) anthracene-9(10H)-one is the most potent compound from Aloin B derivatives as a type-2 antidiabetic agent in the mechanism of inhibiting α-enzyme action pancreatic amylase, based on the value of R2 = 0.980, the PRESS value of the compound was 0.0004, the binding energy value was -7.07 kcal/mol, the inhibition constant was 6.58 uM and the formation of hydrogen bonds between the compound and the amino acid residues aspirin, glycine, threonine and arginine.